FDA May Have Known of Substandard Drugs

Congressional Democrats Say Agency May Have Known of Company's Alleged Fraudulent Conduct Members of Congress are investigating whether the U.S. Food and Drug Administration (FDA) knew about alleged fraudulent data from generic giant Ranbaxy regarding the quality of the company's products. WASHINGTON (Reuters) - Two leading U.S. Democrats said on Tuesday they are investigating whether Food and Drug Administration knowingly allowed the sale of Ranbaxy drugs that may have been backed by fraudulent data. The congressional investigation stems from information released as part of a probe by U.S. law enforcement authorities into whether the Indian drugmaker submitted false data to support generic drug applications and tried to hide manufacturing violations, the lawmakers said. Reps. John Dingell and Bart Stupak said in a statement... [read full story]